CURATED PRIMARY SOURCES
A growing index of peer-reviewed studies and official trial records, organised by molecule and evidence level — with clear boundaries between human data, registered protocols and preclinical research.
The evidence level describes the source design. It does not establish the quality, identity or suitability of a specific product.
SEARCH THE SOURCE, NOT THE CLAIM
Search by molecule, study or identifier. Filters describe study design — not a product rating or recommendation.
Retatrutide
New England Journal of Medicine · PMID 37366315
A randomised, double-blind phase 2 trial in adults with obesity. This is human efficacy and safety evidence for the investigational molecule under the study protocol.
Retatrutide
Nature Medicine · PMID 38858523
A phase 2 substudy using imaging endpoints to assess liver-fat changes. The finding belongs to the studied population, intervention and follow-up period.
Retatrutide
ClinicalTrials.gov · NCT05882045
An official phase 3 study record describing the protocol, endpoints and current status. A registry record must be read separately from company announcements and later peer-reviewed publications.
Tirzepatide
New England Journal of Medicine · PMID 35658024
A 72-week randomised, double-blind phase 3 trial in adults with obesity or overweight. It evaluates a regulated investigational programme, not PeptidsForm product equivalence.
Tirzepatide
Diabetes, Obesity and Metabolism · PMID 39996356
A DXA substudy assessing changes in fat mass and lean mass. A substudy answers a narrower question than the parent trial and should be interpreted within that design.
MOTS-c
Cell Metabolism · PMID 25738459
A foundational experimental study identifying MOTS-c and exploring metabolic effects in cellular and animal models. Preclinical findings are not evidence of clinical benefit in people.
MOTS-c
Cell Metabolism · PMID 29983246
A mechanistic study examining how MOTS-c responds to metabolic stress and interacts with nuclear gene regulation. It develops a biological hypothesis rather than a clinical claim.
Retatrutide
The Lancet · PMID 42250575
A randomised phase 3 study of retatrutide monotherapy in adults with type 2 diabetes. The publication reports trial outcomes; individual treatment decisions remain clinical matters.
Try another molecule, identifier or evidence filter.
EVIDENCE WITHOUT OVERSTATEMENT
A study design determines how confidently a result can be interpreted and how far it can be generalised. Publication alone is not a quality stamp for every claim.
Tests predefined outcomes in participants under a controlled protocol. Relevance remains limited to the studied population, dose, comparator and duration.
Documents the planned protocol, endpoints and status. A registry entry is not a published result and status can change.
Explores biological mechanisms in cells, tissues or animal models. It can support a hypothesis, but cannot establish human clinical benefit.
Research literature does not verify a specific vial. Product identity and analytical results must be linked to the exact lot through its own records.
RESEARCH CONTEXT
The library is an educational index of external sources. Inclusion does not imply endorsement, regulatory approval, product equivalence, clinical suitability or a claim that a PeptidsForm research format produced the published result.
See how a lot is verified→MOLECULE · EVIDENCE · LOT